NASDAQ:AIDX
20/20 Biolabs, Inc.
20/20 Biolabs, Inc.'s revenue grew 16.7% in fiscal 2025 to $2.0M while operating margin rose to −162.9%. The diluted share count rose 2.7%.Summary generated from 20/20 Biolabs, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.0M
Revenue growth+16.7%
Revenue, 5-yr CAGRn/a
Gross margin29.6%
Operating margin−162.9%
Net margin−182.8%
ROICn/a
Return on equity−503.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+2.7%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | 2 | 2 |
| Operating income | −6 | −3 |
| Net income | −6 | −4 |
| Free cash flow | n/a | n/a |
Recent filings
- 8-KResults of a shareholder vote
Sep 18, 2026 - 8-KNotice of delisting or listing-rule failure
Sep 10, 2026 - 8-KRegulation FD disclosure
Sep 2, 2026 - 8-KResults of a shareholder vote
Aug 19, 2026 - 8-KResults of operations and financial condition
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KRegulation FD disclosure
Aug 5, 2026 - 8-KEntry into a material agreement
Jul 22, 2026